摘要
目的探讨单用恩替卡韦片与联用胸腺肽注射液治疗HBeAg阳性的慢性乙型肝炎患者的临床疗效。方法 112例HBeAg阳性的慢性乙型肝炎患者随机分为两组,对照组口服恩替卡韦,治疗组给予恩替卡韦口服,同时给予α1胸腺肽(日达仙)皮下注射,共计12个月,观察各组肝功能,HBVDNA,乙肝三系及不良反应情况。结果恩替卡韦片联用胸腺肽注射液治疗HBeAg阳性的慢性乙型肝炎患者的肝功能复常率,HBV-DNA阴转率,血清HBeAg/抗-Hbe的转变情况较对照组明显好转。结论恩替卡韦联合胸腺肽治疗慢性乙型肝炎是安全和有效的。
OBJECTIVE To investigate the Clinical effects of ETV and thymic peptide threating chronic hepatitis B patients.METHODS 112 Patients were divived into two groups randomly,Treatment group 56 patients were treated with ETV and thymic peptide;control group 56 patients were treated with ETV only.Separately observe liver function,HBVDNA,five terms of Hepatitis B and side effect during six month.RESULTS Liver function and HBVDNA′ improving,the change of HBeAg/anti-Hbe were significantin in the group of ETV and Thymic Peptide treatment.CONCLUSION ETV and Thymic Peptide treatment have significantly effects on Chronic Hepatitis B Patients and were safe.
出处
《海峡药学》
2011年第5期88-90,共3页
Strait Pharmaceutical Journal
